Altogether, our results show that EGFR-TKIs and PD-1/PD-L1 inhibitors induce changes in carnitine, amino acids, fatty acids, and lipids and alter related metabolic pathways in NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.